Additionally, the 36-month beta value for INZY is 2.29. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for INZY is 43.37M and currently, short sellers hold a 8.85% ratio of that float. The average trading volume of INZY on June 04, 2025 was 2.03M shares.
INZY) stock’s latest price update
Inozyme Pharma Inc (NASDAQ: INZY)’s stock price has gone rise by 0.13 in comparison to its previous close of 3.98, however, the company has experienced a 0.76% increase in its stock price over the last five trading days. businesswire.com reported 2025-05-21 that NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozyme Pharma, Inc. (NasdaqGS: INZY) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Inozyme will receive $4.00 in cash for each share of Inozyme that they own. KSF is seeking to determine whether this consideration and the process that.
INZY’s Market Performance
Inozyme Pharma Inc (INZY) has seen a 0.76% rise in stock performance for the week, with a 167.45% gain in the past month and a 234.87% surge in the past quarter. The volatility ratio for the week is 0.26%, and the volatility levels for the past 30 days are at 24.01% for INZY. The simple moving average for the last 20 days is 32.19% for INZY’s stock, with a simple moving average of 37.86% for the last 200 days.
Analysts’ Opinion of INZY
Many brokerage firms have already submitted their reports for INZY stocks, with Raymond James repeating the rating for INZY by listing it as a “Outperform.” The predicted price for INZY in the upcoming period, according to Raymond James is $26 based on the research report published on December 12, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see INZY reach a price target of $16. The rating they have provided for INZY stocks is “Buy” according to the report published on September 12th, 2024.
Jefferies gave a rating of “Buy” to INZY, setting the target price at $17 in the report published on August 13th of the previous year.
INZY Trading at 120.15% from the 50-Day Moving Average
After a stumble in the market that brought INZY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.14% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at INZY starting from Treco Douglas A, who sale 8,819 shares at the price of $0.89 back on Apr 02 ’25. After this action, Treco Douglas A now owns 41,046 shares of Inozyme Pharma Inc, valued at $7,849 using the latest closing price.
Stock Fundamentals for INZY
The total capital return value is set at -2.05. Equity return is now at value -141.69, with -78.44 for asset returns.
Based on Inozyme Pharma Inc (INZY), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -3.66. The debt to equity ratio resting at 0.83. The interest coverage ratio of the stock is -19.04.
Currently, EBITDA for the company is -104.03 million with net debt to EBITDA at -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.19.
Conclusion
In conclusion, Inozyme Pharma Inc (INZY) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high..
